• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Tioga Pharmaceuticals

edit

Tioga Pharmaceuticals, Inc. develops therapies for the treatment of gastrointestinal diseases. Its product includes asimadoline, an orally administered small molecule therapeutic for the treatment of irritable bowel syndrome and functional dyspepsia. The company was founded in 2005 and is based in San Diego, California.

Milestones

edit

• 
  Tioga Pharmaceuticals added David Urso as COO.
  Posted 2/19/10 at 5:02am
• 
  Tioga Pharmaceuticals added Stuart J. M. Collinson as CEO.
  Posted 2/19/10 at 5:02am
• 
  Tioga Pharmaceuticals received $10M in Series B funding. (4/12/12)
  Posted 4/12/12 at 6:06pm via tiogapharma.com
• 
  Tioga Pharmaceuticals received $24M in Series A funding. (1/9/06)
  Posted 4/12/12 at 6:06pm via tiogapharma.com
• 
  Tioga Pharmaceuticals received $18M in Series A funding. (2/17/10)
  Posted 2/19/10 at 5:02am via tiogapharma.com

Videos

Screenshots

edit

Sources

1. Tioga’s Series A Round: $24M For Phase IIb Trial Of IBS Drug (tiogapharma.com) [edit]
2. Tioga Pharmaceuticals, Inc. Raises $18 Million to Fund Phase 3 Clinical Trial in Irritable Bowel Syndrome (tiogapharma.com) [edit]
3. Tioga Pharmaceuticals, Inc. Raises $10 Million to Advance Phase 3 Clinical Development of Asimadoline in Irritable Bowel Syndrome (tiogapharma.com) [edit]